JAK2 and neuropathy: In order to further confirm the involvement of Janus kinase 2 (JAK2) downstream of the CXCR2 pathway [36] in the development of oxaliplatin-induced neuropathy, ruxolitinib, a JAK2 inhibitor, was administered to the oxaliplatin-treated mice (n = 5).